MedPath

Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes

Not Applicable
Completed
Conditions
Type 2 Diabetes
Glucose Metabolism Disorders (Including Diabetes Mellitus)
Energy Supply; Deficiency
Interventions
Other: Weight maintaining isocaloric ketogenic diet
Other: Standard weight maintaining diet
Dietary Supplement: Beta-hydroxy butyrate
Registration Number
NCT04791787
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Brief Summary

The study team will examine the effect of a ketogenic diet alone and ketogenic diet supplemented with oral ketones on how the body of individuals with type 2 diabetes respond to insulin, regulates insulin secretion, food intake and energetic pathways and influences body fat distribution.

Detailed Description

Subjects will be randomized into three groups (1) standard, weight maintaining diet containing approximately 25-35% protein, 45-55% carbohydrate, 20-30% fat; (2) weight maintaining isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate, 70-80% fat; (3) weight maintaining isocaloric diet containing approximately 15-25% protein, 5-10% carbohydrate, 70-80% fat supplemented with the ketone ester of beta-hydroxy butyrate, 8 grams every 8 hours to further increase the plasma ketone concentration by \~3 mM. Subjects will be further randomized on the basis of:

(i) HbA1c 7.0-8.5% and 8.5-10.5% to ensure similar baseline levels of glucose control and (ii) drug naïve versus drug-treated. At the time of screening, after a 10-12 hour overnight fast, indirect calorimetry will be performed with a ventilated hood system for 60 minutes to measure baseline energy expenditure. An initial weight maintenance energy requirement estimate as 1.5 times resting energy expenditure (obtained by indirect calorimetry) will be started. Diets will consist of a 10-day rotating menu using NutriAdmin for meal planning and Nutrition Maker for analysis of recipes Food will be prepared in the Cafeteria and or the Metabolic Kitchen at the Texas Diabetes Institute and certified by a dietician. Subjects will report to the diet kitchen at 8 AM on Monday through Saturday where they will eat their breakfast and pick up food for their lunch and dinner. On Saturday, participants also will be given food for their Sunday meals. Subjects will maintain a daily dietary log with all food consumed. On each visit subjects will be weighed; dietary log will be reviewed and the caloric content of the diet will be adjusted to maintain the body weight constant. Blood pressure will be measured in the reclining position x 2 separate days. Antidiabetic medications will not be changed during the study unless hypoglycemia (fasting plasma glucose \<70 mg/dl or symptoms) occurs. The study duration will be 10 days which should be sufficient to observe the effect of hyperketonemia on glucose/lipid metabolism and energy expenditure. If participant cannot come on the last days of his/her diet treatment, than we will extend this period up to 13 days and participant will be given diet for additional days till completion of the study visits.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  1. Age from 18-70 years
  2. BMI = 27.5-42 kg.m2
  3. HbA1c = 7.0-10.5
  4. Weight stable (±4-5lb) in the preceding 3 months
  5. Good general health
Exclusion Criteria
  1. Use of medications that affect glucose tolerance other than metformin/sulfonylurea/DPP4 Inhibitor
  2. Major organ disease
  3. Estimated Glomerular filtration rate (eGFR) <60 ml/min
  4. Type 1 diabetes
  5. Hematocrit < 34 (if HbA1c is in the 8.5 to 10% range)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Isocaloric Diet with Beta-hydroxy butyrateBeta-hydroxy butyrateIsocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
Isocaloric DietWeight maintaining isocaloric ketogenic dietIsocaloric diet will be provided for 10 days for subjects who are currently treated with a T2DM medication included in the inclusion criteria
Isocaloric Diet with Beta-hydroxy butyrateWeight maintaining isocaloric ketogenic dietIsocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
Standard Weight MaintenanceStandard weight maintaining dietStandard weight maintenance diet will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
Primary Outcome Measures
NameTimeMethod
Hepatic Glucose production (HGP)Baseline to 10 days

Change of hepatic glucose production will be measured using 3H-glucose infusion

Hepatic Fat ContentBaseline to 10 days

Change in hepatic fat content

Fasting plasma glucose (FPG)Baseline to 10 days

A change in FPG will be measured

Total Body FatBaseline to 10 days

Change in whole body fat

Whole Body Fat OxidationBaseline to 10 days

Change in whole body fat oxidation will be measured using indirect calorimetry

Secondary Outcome Measures
NameTimeMethod
C-peptideBaseline to 10 days

Change in C-peptide will be measured

Glycerol levelBaseline to 10 days

Change in Glycerol level will be measured

Glycated hemoglobin test (HbA1c)Baseline to 10 days

Change in HbA1c

Plasma InsulinBaseline to 10 days

Change in plasma insulin will be measured

Free Fatty Acid (FFA)Baseline to 10 days

Change in FFA will be measured

TriglyceridesBaseline to 10 days

Change in triglyceride levels

Fructosamine levelBaseline to 10 days

Change in fructosamine

Low density lipoproteins (LDL)Baseline to 10 days

Change in LDL

High density lipoproteins (HDL)Baseline to 10 days

Change in HDL

Urine Microalbumin excretionBaseline to 10 days

Change in urine microalbumin excretion

Trial Locations

Locations (2)

University Health Systems-Texas Diabetes Institute

🇺🇸

San Antonio, Texas, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath